{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:43:08Z","timestamp":1781664188063,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10557-020-07068-9","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T06:02:48Z","timestamp":1599890568000},"page":"987-993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-0891","authenticated-orcid":false,"given":"Filippo","family":"Angelini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Fortuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Bocchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Franchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"De Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bellettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"D\u2019Ascenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano M.","family":"De Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Paciaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"issue":"2","key":"7068_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/STR.0b013e3181fcb238","volume":"42","author":"LB Goldstein","year":"2011","unstructured":"Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2011;42(2):517\u201384.","journal-title":"Stroke"},{"key":"7068_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0025-6196(12)60336-X","volume":"59","author":"PT Hagen","year":"1984","unstructured":"Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17\u201320.","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"7068_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1161\/CIRCULATIONAHA.104.524371","volume":"112","author":"S Homma","year":"2005","unstructured":"Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005;112(7):1063\u201372.","journal-title":"Circulation"},{"key":"7068_CR4","doi-asserted-by":"crossref","unstructured":"Elgendy AY. MD; Saver JL, Amin Z, et al. proposal for updated nomenclature and classification of potential causative mechanism in patent foramen Ovale-associated stroke. JAMA Neurol. 2020 (Online ahead of print).","DOI":"10.1001\/jamaneurol.2020.0458"},{"issue":"11","key":"7068_CR5","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","volume":"377","author":"JL Saver","year":"2017","unstructured":"Saver JL, Carroll JD, Thaler DE. Long-term outcomes of patent foramen Ovale closure or medical therapy after stroke. N Engl J Med. 2017 Sep 14;377(11):1022\u201332.","journal-title":"N Engl J Med"},{"key":"7068_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","volume":"377","author":"JL Mas","year":"2017","unstructured":"Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs antiplatelets after stroke. N Engl J Med. 2017;377:1011\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"7068_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","volume":"377","author":"L S\u00f8ndergaard","year":"2017","unstructured":"S\u00f8ndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033\u201342.","journal-title":"N Engl J Med"},{"key":"7068_CR8","doi-asserted-by":"crossref","unstructured":"Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol. 2018;71(20):2335\u201342","DOI":"10.1016\/j.jacc.2018.02.046"},{"issue":"7","key":"7068_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2459\/JCM.0000000000000648","volume":"19","author":"F Fortuni","year":"2018","unstructured":"Fortuni F, Crimi G, Leonardi S, et al. Transcatheter closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events: a systematic review and updated meta-analysis of randomized clinical trials. J Cardiovasc Med. 2018;19(7):373\u201381.","journal-title":"J Cardiovasc Med"},{"issue":"13","key":"7068_CR10","first-page":"1389","volume":"14","author":"C Pristipino","year":"2019","unstructured":"Pristipino C, Sievert H, D'Ascenzo F, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Euro Intervent. 2019;14(13):1389\u2013402.","journal-title":"Euro Intervent"},{"key":"7068_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000229553","volume":"28","author":"C Weimar","year":"2009","unstructured":"Weimar C, Holle DN, Benemann J, et al. Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis. 2009;28:349\u201356.","journal-title":"Cerebrovasc Dis"},{"key":"7068_CR12","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1161\/STROKEAHA.108.521427","volume":"39","author":"J Serena","year":"2008","unstructured":"Serena J, Marti-Fabregas J, Santamarina E, et al. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke. 2008;39:3131\u20136.","journal-title":"Stroke"},{"key":"7068_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jnnp.72.3.347","volume":"72","author":"K Nedeltchev","year":"2002","unstructured":"Nedeltchev K, Arnold M, Wahl A, et al. Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry. 2002;72:347\u201350.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7068_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000321334","volume":"31","author":"M Paciaroni","year":"2011","unstructured":"Paciaroni M, Agnelli G, Bertolini A, et al. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. Cerebrovasc Dis. 2011;31:109\u201316.","journal-title":"Cerebrovasc Dis"},{"key":"7068_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijcard.2004.03.005","volume":"101","author":"HW Schuchlenz","year":"2005","unstructured":"Schuchlenz HW, Weihs W, Berghold A, Lechner A, Schmidt R. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol. 2005;101:77\u201382.","journal-title":"Int J Cardiol"},{"key":"7068_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1017\/S0317167100005825","volume":"34","author":"L Casaubon","year":"2007","unstructured":"Casaubon L, McLaughlin P, Webb G, Yeo E, Merker D, Jaigobin C. Recurrent stroke\/TIA in cryptogenic stroke patients with patent foramen ovale. Can J Neurol Sci. 2007;34:74\u201380.","journal-title":"Can J Neurol Sci"},{"key":"7068_CR17","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1161\/01.CIR.0000017498.88393.44","volume":"105","author":"S Homma","year":"2002","unstructured":"Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation. 2002;105:2625\u201331.","journal-title":"Circulation"},{"issue":"12","key":"7068_CR18","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1474-4422(18)30319-3","volume":"17","author":"SE Kasner","year":"2018","unstructured":"Kasner SE, Swaminathan B, Lavados P, et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol. 2018;17(12):1053\u201360.","journal-title":"Lancet Neurol"},{"issue":"20","key":"7068_CR19","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","volume":"380","author":"HC Diener","year":"2019","unstructured":"Diener HC, Sacco RL, Easton JD, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906\u201317.","journal-title":"N Engl J Med"},{"issue":"4","key":"7068_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139 W64.","journal-title":"Ann Intern Med"},{"key":"7068_CR21","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1093\/eurheartj\/ehv252","volume":"36","author":"DM Kent","year":"2015","unstructured":"Kent DM, Dahabreh IJ, Ruthazer R, et al. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J. 2015;36:2381\u20139.","journal-title":"Eur Heart J"},{"key":"7068_CR22","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.","journal-title":"BMJ"},{"issue":"7414","key":"7068_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"7068_CR24","first-page":"366","volume":"l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898:366.","journal-title":"BMJ"},{"key":"7068_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"issue":"2","key":"7068_CR26","first-page":"94","volume":"18","author":"A Shariat","year":"2013","unstructured":"Shariat A, Yaghoubi E, Farazdaghi M, Aghasadeghi K, Borhani Haghighi A. Comparison of medical treatments in cryptogenic stroke patients with patent foramen ovale: a randomized clinical trial. J Res Med Sci. 2013;18(2):94\u20138.","journal-title":"J Res Med Sci"},{"key":"7068_CR27","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1009639","volume":"366","author":"AJ Furlan","year":"2012","unstructured":"Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991\u20139.","journal-title":"N Engl J Med"},{"key":"7068_CR28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","volume":"368","author":"B Meier","year":"2013","unstructured":"Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083\u201391.","journal-title":"N Engl J Med"},{"key":"7068_CR29","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.amjcard.2010.06.066","volume":"106","author":"S De Castro","year":"2010","unstructured":"De Castro S, Papetti F, Di AE, et al. Feasibility and clinical utility of transesophageal echocardiography in the acute phase of cerebral ischemia. Am J Cardiol. 2010;106:1339\u201344.","journal-title":"Am J Cardiol"},{"key":"7068_CR30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1212\/WNL.0b013e31824d58bc","volume":"78","author":"GD Kitsios","year":"2012","unstructured":"Kitsios GD, Lasker A, Singh J, Thaler DE. Recurrent stroke on imaging and presumed paradoxical embolism: a cross-sectional analysis. Neurology. 2012;78:993\u20137.","journal-title":"Neurology"},{"key":"7068_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/STROKEAHA.111.631648","volume":"43","author":"GD Kitsios","year":"2012","unstructured":"Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke. 2012;43:422\u201331.","journal-title":"Stroke"},{"issue":"11","key":"7068_CR32","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1161\/STROKEAHA.119.026512","volume":"50","author":"D Sagris","year":"2019","unstructured":"Sagris D, Georgiopoulos G, Perlepe K, et al. Antithrombotic treatment in cryptogenic stroke patients with patent foramen ovale: systematic review and meta-analysis. Stroke. 2019;50(11):3135\u201340.","journal-title":"Stroke"},{"key":"7068_CR33","doi-asserted-by":"publisher","first-page":"f5133","DOI":"10.1136\/bmj.f5133","volume":"347","author":"LA Castellucci","year":"2013","unstructured":"Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ. 2013;347:f5133.","journal-title":"BMJ"},{"issue":"8","key":"7068_CR34","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0002-9149(97)00604-8","volume":"80","author":"H Lethen","year":"1997","unstructured":"Lethen H, Flachskampf FA, Schneider R, et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol. 1997;80(8):1066\u20139.","journal-title":"Am J Cardiol"},{"key":"7068_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1161\/01.STR.0000106137.42649.AB","volume":"35","author":"SC Cramer","year":"2004","unstructured":"Cramer SC, Rordorf G, Maki JH, et al. Increased pelvic vein thrombi in cryptogenic stroke: results of the paradoxical emboli from large veins in ischemic stroke (PELVIS) study. Stroke. 2004;35:46\u201350.","journal-title":"Stroke"},{"key":"7068_CR36","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.jacc.2013.07.084","volume":"62","author":"A Gaspardone","year":"2013","unstructured":"Gaspardone A, Giardina A, Iamele M, et al. Effect of percutaneous closure of patent foramen ovale on post-procedural arrhythmias. J Am Coll Cardiol. 2013;62:2449\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"7068_CR37","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903\u201312.","journal-title":"Lancet"},{"key":"7068_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11886-018-1053-0","volume":"20","author":"MSV Elkind","year":"2018","unstructured":"Elkind MSV. Atrial cardiopathy and stroke prevention. Curr Cardiol Rep. 2018;20:103.","journal-title":"Curr Cardiol Rep"},{"key":"7068_CR39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T van der Hulle","year":"2014","unstructured":"van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12:320\u20138.","journal-title":"J Thromb Haemost"},{"key":"7068_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijcard.2018.08.019","volume":"273","author":"F Fortuni","year":"2018","unstructured":"Fortuni F, Ferlini M, Leonardi S, et al. Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: a systematic review and meta-analysis. Int J Cardiol. 2018;273:80\u20137.","journal-title":"Int J Cardiol"},{"key":"7068_CR41","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.4244\/EIJV9I12A239","volume":"9","author":"V Rudolph","year":"2014","unstructured":"Rudolph V, Augustin J, Hofmann T, et al. Predictors of recurrent stroke after percutaneous closure of patent foramen ovale. Eurolntervention. 2014;9:1418\u201322.","journal-title":"Eurolntervention"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07068-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07068-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07068-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T05:18:34Z","timestamp":1632115114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07068-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["7068"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07068-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,12]]},"assertion":[{"value":"27 August 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Giancarlo Agnelli received honoraria as a member of the speaker bureau of Boehringer Ingelheim and Bayer. Maurizio Paciaroni received honoraria as a member of the speaker bureau of Sanofi-Aventis, Boehringer Ingelheim, Bayer, Bristol Meyer Squibb, and Pfizer. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}